Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Not Approvable” Letter Questions Benefit Of Endo’s Frova In Menstrual Migraine

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency indicates potential for vascular events is another reason frovatriptan is "not approvable" for short-term prevention of menstrual migraine.

You may also be interested in...



GSK’s Treximet Could Face Market Headaches

Potential hurdles for Pozen-partnered migraine combo drug include BiDil-like woes and switchover problems.

GSK’s Treximet Could Face Market Headaches

Potential hurdles for Pozen-partnered migraine combo drug include BiDil-like woes and switchover problems.

Endo Withdraws Frova sNDA For Menstrual Migraine Prevention

Action comes days after former Johnson & Johnson exec Holveck takes the helm as president and CEO.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel